RxDoctor Payments DataLook up a doctor →

Marcus Tielker, MD

Pulmonary Disease · Indianapolis, INNPI 1124263215

Payments from drug & device makers

$11,182in general payments, 2019–2025

Across 618 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$2K
  • Boehringer Ingelheim$1K
  • Grifols USA, LLC$651
  • Sanofi$600
  • Johnson & Johnson$543
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$11,11099%
  • Education$721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,182 in reported general payments places this provider in the 75th percentile of 258 pulmonary disease providers in Indiana.

See all pulmonary disease providers in Indiana

Medicare billing

Part B allowed, 2024
$118,534
Medicare patients
432
Services billed
1,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter266$284,238
OfevNintedanib Esylate19$251,971
Breo ElliptaFluticasone/Vilanterol73$40,561
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr52$35,250
EliquisApixaban21$24,342
Stiolto RespimatTiotropium Br/Olodaterol Hcl30$22,481
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$17,690
Combivent RespimatIpratropium/Albuterol Sulfate13$17,159
SymbicortBudesonide/Formoterol Fumarate40$14,463
Arnuity ElliptaFluticasone Furoate16$4,915
Albuterol Sulfate HfaAlbuterol Sulfate190$4,805
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate37$4,167
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$3,210
Ventolin HfaAlbuterol Sulfate33$1,968
Wixela InhubFluticasone Propion/Salmeterol11$1,324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$1,626$364,964407 claims
Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat$1,323$291,61062 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,634$32,15358 claims
PfizerEliquis$63$24,34221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 258 pulmonary disease providers in Indiana.

Other pulmonary disease in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →